Home
    • Plans Blog Contact
    Regencell Bioscience Holdings Ltd logo

    Regencell Bioscience Holdings Ltd

    RGC
    Last price US$5.64
    Market cap US$2.8b
    12M price change -62.85%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Zoetis IncZTS Industry peer Amphastar PAMPH Industry peer Prestige Consumer HealthcarePBH Industry peer IQVIA Holdings IncIQV Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Regencell Bioscience Holdings Ltd Overview

    Industry: Drug Manufacturers Specialty & Generic

    Sector: Healthcare

    Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and auti Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Regencell Bioscience Holdings Ltd into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 22, 2026

    Quarterly result summary

    Exhibit 99.1 Regencell Bioscience Holdings Limited Announces Closing of Registered Direct Offering of Ordinary Shares HONG KONG, May 22, 2026 – Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”) announced the closing of a registered direct of...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings material Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 22, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 19, 2026 Earnings material PRESS RELEASE - REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES REGISTERED DIRECT OFFERING OF ORDINARY SHARES May 19, 2026 Earnings release REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES FIRST HALF 2026 MANAGEMENT FINANCIAL RESULTS May 08, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Mar 30, 2026 Earnings material PRESS RELEASE - REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES AT-THE-MARKET OFFERING OF ORDINARY SHARES Mar 30, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    Regencell Bioscience Holdings Ltd earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Return on Equity

    Score 1.51/5
    Regencell Bioscience Holdings Ltd exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Regencell Bi... RGC US$2.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Regencell Bioscience Holdings Ltd olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Regencell Bi... RGC US$2.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

    Leverage

    Score 4.12/5
    Regencell Bioscience Holdings Ltd attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Regencell Bi... RGC US$2.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Regencell Bioscience Holdings Ltd logo

    Regencell Bioscience Holdings Ltd

    US$5.64

    US$2.8b

    12.24%

    -62.85%